The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease

Biol Blood Marrow Transplant. 2017 Feb;23(2):211-234. doi: 10.1016/j.bbmt.2016.09.023. Epub 2016 Oct 3.

Abstract

Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality and disability in allogeneic hematopoietic cell transplantation recipients and a major obstacle to improving outcomes. The biology of chronic GVHD remains enigmatic, but understanding the underpinnings of the immunologic mechanisms responsible for the initiation and progression of disease is fundamental to developing effective prevention and treatment strategies. The goals of this task force review are as follows: This document is intended as a review of our understanding of chronic GVHD biology and therapies resulting from preclinical studies, and as a platform for developing innovative clinical strategies to prevent and treat chronic GVHD.

Keywords: Blood and marrow transplantation; Chronic graft-versus-host disease; Clinical manifestations; Immune mechanisms.

Publication types

  • Review

MeSH terms

  • Allografts
  • Animals
  • Biomarkers
  • Chronic Disease
  • Clinical Trials as Topic / standards*
  • Cytokines / metabolism
  • Endothelium, Vascular / pathology
  • Fibrosis
  • Graft vs Host Disease* / etiology
  • Graft vs Host Disease* / immunology
  • Graft vs Host Disease* / pathology
  • Graft vs Host Disease* / therapy
  • Humans
  • Inflammation
  • Interferon-gamma / physiology
  • Mice
  • Models, Animal
  • Models, Immunological
  • Organ Specificity
  • T-Lymphocyte Subsets / immunology
  • Terminology as Topic
  • Transplantation Immunology
  • Wound Healing

Substances

  • Biomarkers
  • Cytokines
  • Interferon-gamma